- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03569579
CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1)
A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Effect of D797 on Pharmacokinetics of D324 in Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Jeonju, Korea, Republic of
- Chonbuk National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A healthy adult whose age is over 19 years old when visiting for initial screening test
- Body mass index(BMI) between 17.5~30.5 kg/m^2 and the body weight must be over 55kg (Body mass index (BMI) = weight (kg) / height (m)^2)
- A person with no congenital or chronic disease in three years, no history of symptoms in internal treatment, or no knowledge in the area
- Due to the special characteristics of drugs, the participators must be qualified to do the clinical screening after examined through hematology test and blood chemistry analysis, urinary test, the electrocardiogram (ECG), and etc.
- The participants must be volunteered and sign in an informed consent document proven by Chonbuk National University IRB before joining a study to show that he was given informed the purpose of tests and the special characteristics of drugs.
- The participants must have an ability and willingness to participate throughout the entire trials
Exclusion Criteria:
- A person who had a history or symptoms of clinically aware of blood, kidney, internal secretion, gastrointestinal, urinary system, cardiovascular, liver, mental, nercous, or allergic(except subclinical seasonal allergies that is not treated at injecion) desease.
- Who had a gistory of gastrointestinal related disease which can be affected the drug absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's disease) or surgeries (except a simple appendectomy or herniotomy)
Who had following results after examination
a. ALT or AST > twice higher than normal value
- Who constantly intake 210 g/week of alcohol within 6 months of the screening. (a cup of beer (5%) (250 mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a glass of wine (!2%) (125 mL) = 12g)
- Who participated other clinical test or took testing bioequivalence drugs in 3 months before the first clinical drug trial.
- Whose blood pressure < 100 or ≥140(systolic blood pressure) or < 70 or ≥ 90(diastolic blood pressure)
- Who had a medical history of alcohol and drug abuses.
- Who had taken a drug that has a control of metabolic rate (activatioh or inhibithion) in 30 days before the first taking of clinical testing durg.
- Who smokes more than 10 eigarettes per day.
- Who took prescribed drugs or over-the-conuter durgs in 10 days before taking of very first clinical testing drug.
- Who participated in whole blood donation in 2 months before the first taking of clinical testing drugs or platelet donations in 1 month before the first taking to clinical testing drugs.
- Who has a potent to increase a danger by participating in the clinical trials or sho can interrupt interpretin test results by having serious or chronic medical and mental status or having issues in results of the screening examination.
Who has a histroy of an extreme sensitivity of drugs that contain donepezil hydrochloride, piperidine derivatives, memantine hydrochloride drugs.
Who has a serious heart failure or a congestive heart failure that must be drug-treated
- Who has a Pregnant or potentially pregnant.
- Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders.
- A patient with severe hepatopathy
- A patient with moderate nephropathy.
- A person who is not determined unsuitable to participate in this test by the researchers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1(Treatment A/Treatment B)
Period 1: Treatment A(Memantine Tab. 10mg)*2T, QD, PO. Period 2: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO. Each treatment period was separated by a washout period of at least 21 dyas. |
Memantine Tab.
10mg* 2T/day, QD, PO
Other Names:
Memantine Tab.
10mg* 2T/day + Donepezil Tab.
10mg * 1T/day, QD, PO
Other Names:
|
Experimental: Group 1(Treatment B/Treatment A)
Period 1: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO. Period 2: Treatment A(Memantine Tab. 10mg)*1T, QD, PO. Each treatment period was separated by a washout period of at least 21 dyas. |
Memantine Tab.
10mg* 2T/day, QD, PO
Other Names:
Memantine Tab.
10mg* 2T/day + Donepezil Tab.
10mg * 1T/day, QD, PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCt of Memantine
Time Frame: 1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
Area under the plasma concentration of Memantine versus time curve from time zero to time of last quantifiable concentration
|
1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
Cmax of Memantine
Time Frame: 1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
Maximum plasma concentration of Memantine
|
1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCinf of Memantine
Time Frame: 1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
Area under the plasma concentration of Memantine versus time curve from time zero to time infinity
|
1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
Tmax of Memantine
Time Frame: 1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
Time to maximum concentration of of Memantine
|
1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
t1/2 of Memantine
Time Frame: 1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
Apparent terminal half-life of Memantine
|
1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
CL/F of Memantine
Time Frame: 1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
Total body clearance of Memantine
|
1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
Vd/F of Memantine
Time Frame: 1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
Apparent volume of distribution of Memantine
|
1Day 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 24h, 48h, 72h, 120h, 168h, 216h
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kyung-Ho Jang, Professor, Chonbuk National University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Central Nervous System Diseases
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Enzyme Inhibitors
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Dopamine Agents
- Nootropic Agents
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Cholinesterase Inhibitors
- Donepezil
- Memantine
Other Study ID Numbers
- 179DDI18002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Nervous System Diseases
-
Bracco Diagnostics, IncCompletedCentral Nervous System Neoplasms | Central Nervous System Disease
-
Weill Medical College of Cornell UniversityRecruitingCentral Nervous System Tumor | Pediatric Central Nervous System TumorUnited States
-
Bracco Diagnostics, IncCompletedCentral Nervous System Diseases | Central Nervous System NeoplasmsUnited States
-
Bracco Diagnostics, IncCompletedCentral Nervous System Diseases | Central Nervous System NeoplasmsUnited States
-
Washington University School of MedicineRecruitingCentral Nervous SystemUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingCentral Nervous System TumorUnited States
-
Washington University School of MedicineLloyd J. Old STAR ProgramTerminatedCentral Nervous System Neoplasms | Central Nervous System TumorUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingMalignant Central Nervous System NeoplasmUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedSuspected Central Nervous System TumorsUnited States
-
Children's Oncology GroupRecruitingCentral Nervous System CarcinomaUnited States, Puerto Rico
Clinical Trials on Memantine Tab. 10mg
-
Chong Kun Dang PharmaceuticalUnknownType II Diabetes MellitusKorea, Republic of
-
Chinese University of Hong KongRecruitingChronic Hepatitis BHong Kong
-
HK inno.N CorporationCompleted
-
Chong Kun Dang PharmaceuticalCompletedHypertension | DyslipidemiasKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompleted
-
Daewon Pharmaceutical Co., Ltd.CompletedHypercholesterolemia, DyslipidemiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedAlzheimer's Disease (AD)Korea, Republic of
-
Region Örebro CountyLondon School of Hygiene and Tropical Medicine; Odense University Hospital; Göteborg... and other collaboratorsRecruitingAtrial Fibrillation | Chronic Coronary SyndromeDenmark, Sweden, Czechia
-
Fondazione IRCCS Policlinico San Matteo di PaviaRecruiting